secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001683168-23-001648
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign reports FY2022 revenue $38.0M (+29% YoY), net income $1.0M; guides FY2023 revenue $44-46M
--------------------------------------------------------------------------------

- Full-year 2022 revenue $38.0M, up 29% YoY; net income $1.0M ($0.02 diluted EPS) vs net loss of $2.7M in 2021.
- Adjusted EBITDA $5.5M, up 175% from $2.0M; Q4 revenue $10.6M, up 21%; Q4 adjusted EBITDA $1.7M, up 38%.
- Board authorized $5M share repurchase program; added 78 net plasma centers in 2022, ending with 444.
- FY2023 guidance: revenue $44-46M, net income $2.5-3.5M ($0.05-0.06 diluted EPS), adjusted EBITDA $6.0-7.5M.
- Pharma copay revenue up 145% to $1.5M; launched 10 new pharma copay programs in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316823001648/0001683168-23-001648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316823001648/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-001648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer